A benefit-risk assessment of the use of proton pump inhibitors in the elderly

Drugs and Aging

Volumn 31, Issue 4, 2014, Pages 263-282

  Masclee, Gwen M C ^a   Sturkenboom, Miriam C J M ^a   Kuipers, Ernst J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; CLOPIDOGREL; CORTICOSTEROID; CYANOCOBALAMIN; CYTOCHROME P450 2C19; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; LEVOTHYROXINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ACUTE HEART INFARCTION; ADVERSE OUTCOME; AGED; AGING; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BARRETT ESOPHAGUS; CALCIUM ABSORPTION; CARDIOVASCULAR DISEASE; CLOSTRIDIUM DIFFICILE INFECTION; CONFIDENCE INTERVAL; CONSTIPATION; CYANOCOBALAMIN DEFICIENCY; DEATH; DIARRHEA; DRUG ABSORPTION; DRUG COST; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; DRUG USE; DYSPEPSIA; ERADICATION THERAPY; ESOPHAGITIS; FRACTURE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; GERIATRIC PATIENT; HAZARD RATIO; HEADACHE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HYPOMAGNESEMIA; INTERSTITIAL NEPHRITIS; INTESTINE INFECTION; IRON ABSORPTION; LOW DRUG DOSE; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; NAUSEA; NUTRITIONAL STATUS; PEPTIC ULCER; PHARMACOEPIDEMIOLOGY; PNEUMONIA; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; RACE DIFFERENCE; RASH; REFLUX ESOPHAGITIS; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; STOMACH PH; SYSTEMATIC REVIEW (TOPIC); THROMBOCYTE FUNCTION; UPPER GASTROINTESTINAL BLEEDING; VITAMIN DEFICIENCY; ZOLLINGER ELLISON SYNDROME;

AGED; AGING; ANIMALS; DRUG INTERACTIONS; HUMANS; INAPPROPRIATE PRESCRIBING; PROTON PUMP INHIBITORS; RISK ASSESSMENT;

EID: 84898778423     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-014-0166-4     Document Type: Review

References (171)

1. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005;100(1):190-200.
2. IMS Health Report. declining medicine use and costs: for better or worse? New Jersey: IMS; 2013. http://www.imshealth.com/cds/ims/Global/Content/ Insights/IMS%20Institute%20for%20Healthcare%20Informatics/2012%20U.S. %20Medicines%20Report/2012-U.S.Medicines-Report.pdf. Accessed 21th Aug 2013.
3. National college of health insurances. http://www.gipdatabank.nl/ databank.asp. Accessed 5th Aug 2013.
4. Pilotto A, Franceschi M, Vitale D, Zaninelli A, Masotti G, Rengo F. Drug use by the elderly in general practice: effects on upper gastrointestinal symptoms. Eur J Clin Pharmacol. 2006;62(1):65-73.
5. Cerreta F, Eichler HG, Rasi G. Drug policy for an aging population - the European Medicines Agency's geriatric medicines strategy. N Engl J Med. 2012;367(21):1972-4.
6. Shakir SA, Layton D. Causal association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford-Hill criteria. Drug Saf. 2002;25(6):467-71.
7. Van Soest EM, Siersema PD, Dieleman JP, Sturkenboom MC, Kuipers EJ. Persistence and adherence to proton pump inhibitors in daily clinical practice. Aliment Pharmacol Ther. 2006;24(2):377-85.
8. Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharm Ther. 2000;25(5):333-40.
9. Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104(3):728-38.
10. Valkhoff VE, van Soest EM, Masclee GM, de Bie S, Mazzaglia G, Molokhia M, et al. Prescription of nonselective NSAIDs, coxibs and gastroprotective agents in the era of rofecoxib withdrawal - a 617,400-patient study. Aliment Pharmacol Ther. 2012;36(8):790-9.
11. de Abajo FJ, Garcia Rodriguez LA. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol. 2001;1(1):1-8.
12. Cea Soriano L, Rodriguez LA. Risk of upper gastrointestinal bleeding in a cohort of new users of low-dose ASA for secondary prevention of cardiovascular outcomes. Front Pharmacol. 2012;1(126):1-9.
13. Lanas A, Garcia-Rodriguez LA, Arroyo MT, Gomollon F, Feu F, Gonzalez-Perez A, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut. 2006;55(12):1731-8.
14. Lanas A, Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin. 2007;23(1):163-73.
15. Hedberg J, Sundstrom J, Thuresson M, Aarskog P, Oldgren J, Bodegard J. Low-dose acetylsalicylic acid and gastrointestinal ulcers or bleeding-a cohort study of the effects of proton pump inhibitor use patterns. J Intern Med. 2013;274(4):371-80.
16. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2008;118(18):1894-909.
17. de Jong HJ, Korevaar JC, van Dijk L, Voogd E, van Dijk CE, van Oijen MG. Suboptimal prescribing of proton-pump inhibitors in low-dose aspirin users: a cohort study in primary care. BMJ Open. 2013;3(7) 3003044
18. van Soest EM, Valkhoff VE, Mazzaglia G, Schade R, Molokhia M, Goldstein JL, et al. Suboptimal gastroprotective coverage of NSAID use and the risk of upper gastrointestinal bleeding and ulcers: an observational study using three European databases. Gut. 2011;60(12):1650-9.
19. Barkun AN, Bardou M, Kuipers EJ, Sung J, Hunt RH, Martel M, et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med. 2010;152(2):101-13.
20. Masclee GM, Valkhoff VE, van Soest EM, Schade R, Mazzaglia G, Molokhia M, et al. Cyclo-oxygenase-2 inhibitors or nonselective NSAIDs plus gastroprotective agents: what to prescribe in daily clinical practice? Aliment Pharmacol Ther. 2013;38(2):178-89.
21. García Rodríguez LA, Hernández-Díaz S. The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. Arthritis Res. 2001;3(2):96-101.
22. Hernandez-Diaz S, Rodriguez LA. Steroids and risk of upper gastrointestinal complications. Am J Epidemiol. 2001;153(11):1089-93.
23. Hallas J, Dall M, Andries A, Andersen BS, Aalykke C, Hansen JM, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ. 2006;333(7571):726.
24. Vogiagis D, Glare EM, Misajon A, Brown W, O'Brien PE. Cyclooxygenase-1 and an alternatively spliced mRNA in the rat stomach: effects of aging and ulcers. Am J Physiol Gastrointest Liver Physiol. 2000;278(5):G820-7.
25. Cryer B, Redfern JS, Goldschmiedt M, Lee E, Feldman M. Effect of aging on gastric and duodenal mucosal prostaglandin concentrations in humans. Gastroenterology. 1992;102:1118-23.
26. Cryer G, Lee E, Feldman M. Factors influencing gastroduodenal mucosal prostaglandin concentrations: roles of smoking and aging. Ann Intern Med. 1992;116(8):636-40.
27. Fass R, Pulliam G, Johnson C, Garewal HS, Sampliner RE. Symptom severity and oesophageal chemosensitivity to acid in older and young patients with gastro-oesophageal reflux. Age Ageing. 2000;29(2):125-30.
28. Lasch H, Castell DO, Castell JA. Evidence for diminished visceral pain with aging: studies using graded intraesophageal balloon distension. Am J Physiol. 1997;272(1 Pt 1):G1-3.
29. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, Havu N, Festen HP, Liedman B, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med. 1996;334(16):1018-22.
30. Berstad AE, Hatlebakk JG, Maartmann-Moe H, Berstad A, Brandtzaeg P. Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole. Gut. 1997;41(6):740-7.
31. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, et al. Management of Helicobacter pylori infection - the Maastricht IV/Florence consensus report. Gut. 2012;61(5):646-64.
32. Bell JS, Strandberg TE, Teramura-Gronblad M, Laurila JV, Tilvis RS, Pitkala KH. Use of proton pump inhibitors and mortality among institutionalized older people. Arch Intern Med. 2010;170(17):1604-5.
33. Teramura-Gronblad M, Bell JS, Poysti MM, Strandberg TE, Laurila JV, Tilvis RS, et al. Risk of death associated with use of PPIs in three cohorts of institutionalized older people in Finland. J Am Med Dir Assoc. 2012;13(5):488 e9-13.
34. Maggio M, Corsonello A, Ceda GP, Cattabiani C, Lauretani F, Butto V, et al. Proton pump inhibitors and risk of 1-year mortality and rehospitalization in older patients discharged from acute care hospitals. JAMA Intern Med. 2013;173(7):518-23.
35. Teramura-Gronblad M, Hosia-Randell H, Muurinen S, Pitkala K. Use of proton-pump inhibitors and their associated risks among frail elderly nursing home residents. Scand J Prim Health Care. 2010;28(3):154-9.
36. Cherubini A, Oristrell J, Pla X, Ruggiero C, Ferretti R, Diestre G, et al. The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. Arch Intern Med. 2011;171(6):550-6.
37. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ. 1996;312(7040):1215-8.
38. Noguerado Asensio A, Rodriguez Barrientos R, Zelaya Castro P, Sanchez Sempere A, Antuna Blanco F, Lutz Garcia E, et al. Use of acid-suppressive medications in hospitalized patients. An Med Interna. 2002;19(11):557-60.
39. Pasina L, Nobili A, Tettamanti M, Salerno F, Corrao S, Marengoni A, et al. Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly. Eur J Intern Med. 2011;22(2):205-10.
40. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008;336(7634):2-3.
41. Gupta R, Garg P, Kottoor R, Munoz JC, Jamal MM, Lambiase LR, et al. Overuse of acid suppression therapy in hospitalized patients. South Med J. 2010;103(3):207-11.
42. Parsons C, Johnston S, Mathie E, Baron N, Machen I, Amador S, et al. Potentially inappropriate prescribing in older people with dementia in care homes: a retrospective analysis. Drugs Aging. 2012;29(2):143-55.
43. Glew CM, Rentler RJ. Use of proton pump inhibitors and other acid suppressive medications in newly admitted nursing facility patients. J Am Med Dir Assoc. 2007;8(9):607-9.
44. Hamzat H, Sun H, Ford JC, Macleod J, Soiza RL, Mangoni AA. Inappropriate prescribing of proton pump inhibitors in older patients: effects of an educational strategy. Drugs Aging. 2012;29(8):681-90.
45. Sebastian SS, Kernan N, Qasim A, O'Morain CA, Buckley M. Appropriateness of gastric antisecretory therapy in hospital practice. Ir J Med Sci. 2003;172(3):115-7.
46. Lampen-Smith A, Young J, O'Rourke MA, Balram A, Inns S. Blinded randomised controlled study of the effect of a discharge communication template on proton pump inhibitor prescribing. N Z Med J. 2012;125(1350):30-6.
47. Ahrens D, Chenot JF, Behrens G, Grimmsmann T, Kochen MM. Appropriateness of treatment recommendations for PPI in hospital discharge letters. Eur J Clin Pharmacol. 2010;66(12):1265-71.
48. Klok RM, Brouwers JR, Van den Berg PB, De Jong-Van den Berg LT, Tolley K, Postma MJ. Continued utilization and costs of proton pump inhibitors after Helicobacter pylori eradication in chronic users of gastrointestinal drugs. Aliment Pharmacol Ther. 2002;16(5):1033-4.
49. Williams D, O'Kelly P, Kelly A, Feely J. Lack of symptom benefit following presumptive Helicobacter pylori eradication therapy in primary care. Aliment Pharmacol Ther. 2001;15(11):1769-75.
50. Hungin AP, Rubin GP, O'Flanagan H. Long-term prescribing of proton pump inhibitors in general practice. Br J Gen Pract. 1999;49(443):451-3.
51. Inadomi JM, Jamal R, Murata GH, Hoffman RM, Lavezo LA, Vigil JM, et al. Step-down management of gastroesophageal reflux disease. Gastroenterology. 2001;121(5):1095-100.
52. Murie J, Allen J, Simmonds R, de Wet C. Glad you brought it up: a patient-centred programme to reduce proton-pump inhibitor prescribing in general medical practice. Qual Prim Care. 2012;20(2):141-8.
53. Pollock K, Grime J. Strategies for reducing the prescribing of proton pump inhibitors (PPIs): patient self-regulation of treatment may be an under-exploited resource. Soc Sci Med. 2000;51(12):1827-39.
54. Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med. 1998;129(12):1027-30.
55. Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet. 2005;20(3):153-67.
56. Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T. Pharmacogenomics of proton pump inhibitors. Pharmacogenomics. 2004;5(2):181-202.
57. Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs. 2003;63(24):2739-54.
58. Klotz U, Schwab M, Treiber G. CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol. 2004;95(1):2-8.
59. Hunfeld NG, Touw DJ, Mathot RA, Mulder PG, VANS RH, Kuipers EJ, et al. A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism. Aliment Pharmacol Ther. 2010;31(1):150-9.
60. Hunfeld NG, Touw DJ, Mathot RA, van Schaik RH, Kuipers EJ. A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism. Aliment Pharmacol Ther. 2012;35(7):810-8.
61. Furuta T, Shirai N, Watanabe F, Honda S, Takeuchi K, Iida T, et al. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther. 2002;72(4):453-60.
62. Hunfeld NG, Mathot RA, Touw DJ, van Schaik RH, Mulder PG, Franck PF, et al. Effect of CYP2C192 and 17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians. Br J Clin Pharmacol. 2008;65(5):752-60.
63. Andersson T, Hassan-Alin M, Hasselgren G, Rohss K. Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet. 2001;40(7):523-37.
64. Canada R. Prescribing information Tarceva (erlotinib). http://www.gene.com/gene/products/information/pdf/tarceva-prescribing.pdf. Accessed 19th August 2013.
65. McCabe SM, Smith PF, Ma Q, Morse GD. Drug interactions between proton pump inhibitors and antiretroviral drugs. Expert Opin Drug Metab Toxicol. 2007;3(2):197-207.
66. Food and Drug Administration. Public Health Advisory: updated safety information about a drug interaction between clopidogrel bisulfate (marketed as Plavix) and omeprazole (marketed as Prilosec and Prilosec OTC). http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm190825. htm. Accessed 7 Aug 2013.
67. European Medicines Agency. Public statement on possible interaction between clopidogrel and proton pump inhibitors. http://www.ema.europa.eu/docs/ en-GB/document-library/Public-statement/2009/11/WC500014409.pdf. Accessed 7 Aug 2013.
68. Kwok CS, Loke YK. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther. 2010;31(8):810-23.
69. Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, et al. Cytochrome 2C1917 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation. 2010;121(4):512-8.
70. Kwok CS, Jeevanantham V, Dawn B, Loke YK. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. Int J Cardiol. 2013;167(3):965-74.
71. Strom BL, Kimmel SE, editors. Textbook of pharmacoepidemiology. Chichester: Wiley; 2006.
72. Valkhoff VE, Jong GW, Van Soest EM, Kuipers EJ, Sturkenboom MC. Risk of recurrent myocardial infarction with the concomitant use of clopidogrel and proton pump inhibitors. Aliment Pharmacol Ther. 2011;33(1):77-88.
73. Charlot M, Grove EL, Hansen PR, Olesen JB, Ahlehoff O, Selmer C, et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ. 2011;342:d2690.
74. Wurtz M, Grove EL, Kristensen SD, Hvas AM. The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. Heart. 2010;96(5):368-71.
75. Adamopoulos AB, Sakizlis GN, Nasothimiou EG, Anastasopoulou I, Anastasakou E, Kotsi P, et al. Do proton pump inhibitors attenuate the effect of aspirin on platelet aggregation? A randomized crossover study. J Cardiovasc Pharmacol. 2009;54(2):163-8.
76. Garcia Rodriguez LA, Johansson S, Nagy P, Cea Soriano L. Use of proton pump inhibitors and the risk of coronary events in new users of low-dose acetylsalicylic acid in UK primary care. Thromb Haemost. 2014;111(1):131-9.
77. Azizi F, Belur R, Albano J. Malabsorption of thyroid hormones after jejunoileal bypass for obesity. Ann Intern Med. 1979;90(6):941-2.
78. Centanni M, Gargano L, Canettieri G, Viceconti N, Franchi A, Delle Fave G, et al. Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N Engl J Med. 2006;354(17):1787-95.
79. Liwanpo L, Hershman JM. Conditions and drugs interfering with thyroxine absorption. Best Pract Res Clin Endocrinol Metab. 2009;23(6):781-92.
80. Singh N, Singh PN, Hershman JM. Effect of calcium carbonate on the absorption of levothyroxine. JAMA. 2000;283(21):2822-5.
81. Sachmechi I, Reich DM, Aninyei M, Wibowo F, Gupta G, Kim PJ. Effect of proton pump inhibitors on serum thyroid-stimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism. Endocr Pract. 2007;13(4):345-9.
82. Dietrich JW, Gieselbrecht K, Holl RW, Boehm BO. Absorption kinetics of levothyroxine is not altered by proton-pump inhibitor therapy. Horm Metab Res. 2006;38(1):57-9.
83. Ananthakrishnan S, Braverman LE, Levin RM, Magnani B, Pearce EN. The effect of famotidine, esomeprazole, and ezetimibe on levothyroxine absorption. Thyroid. 2008;18(5):493-8.
84. Brajkovich IE, Mashiter K, Joplin GF, Cassar J. Serum T4, T3, and TSH levels in primary hypothyroidism during replacement therapy with thyroxine. Metabolism. 1983;32(8):745-7.
85. Diamantopoulos AP, Hoff M, Skoie IM, Hochberg M, Haugeberg G. Short- and long-term mortality in males and females with fragility hip fracture in Norway. A population-based study. Clin Interv Aging. 2013;8:817-23.
86. Haleem S, Lutchman L, Mayahi R, Grice JE, Parker MJ. Mortality following hip fracture: trends and geographical variations over the last 40 years. Injury. 2008;39(10):1157-63.
87. Korhonen N, Niemi S, Parkkari J, Sievanen H, Palvanen M, Kannus P. Continuous decline in incidence of hip fracture: nationwide statistics from Finland between 1970 and 2010. Osteoporos Int. 2013;24(5):1599-603.
88. Kannus P, Parkkari J, Sievanen H, Heinonen A, Vuori I, Jarvinen M. Epidemiology of hip fractures. Bone. 1996;18(1 Suppl):57S-63S.
89. Chonan O, Takahashi R, Yasui H, Watanuki M. Effect of l-lactic acid on calcium absorption in rats fed omeprazole. J Nutr Sci Vitaminol (Tokyo). 1998;44(3):473-81.
90. Tuukkanen J, Vaananen HK. Omeprazole, a specific inhibitor of H + -K + -ATPase, inhibits bone resorption in vitro. Calcif Tissue Int. 1986;38(2):123-5.
91. Mizunashi K, Furukawa Y, Katano K, Abe K. Effect of omeprazole, an inhibitor of H+, K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int. 1993;53(1):21-5.
92. Ensrud KE, Duong T, Cauley JA, Heaney RP, Wolf RL, Harris E, et al. Low fractional calcium absorption increases the risk for hip fracture in women with low calcium intake. Study of Osteoporotic Fractures Research Group. Ann Intern Med. 2000;132(5):345-53.
93. O'Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med. 2005;118(7):778-81.
94. Yang YX. Chronic proton pump inhibitor therapy and calcium metabolism. Curr Gastroenterol Rep. 2012;14(6):473-9.
95. Targownik LE, Lix LM, Leung S, Leslie WD. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology. 2010;138(3):896-904.
96. Yu EW, Blackwell T, Ensrud KE, Hillier TA, Lane NE, Orwoll E, et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int. 2008;83(4):251-9.
97. Roux C, Briot K, Gossec L, Kolta S, Blenk T, Felsenberg D, et al. Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int. 2009;84(1):13-9.
98. Gray SL, LaCroix AZ, Larson J, Robbins J, Cauley JA, Manson JE, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med. 2010;170(9):765-71.
99. Roux C, Goldstein JL, Zhou X, Klemes A, Lindsay R. Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors. Osteoporos Int. 2012;23(1):277-84.
100. Ozdil K, Kahraman R, Sahin A, Calhan T, Gozden EH, Akyuz U, et al. Bone density in proton pump inhibitors users: a prospective study. Rheumatol Int. 2013;33(9):2255-60.
101. Maggio M, Lauretani F, Ceda GP, De Vita F, Bondi G, Corsonello A, et al. Use of proton pump inhibitors is associated with lower trabecular bone density in older individuals. Bone. 2013;57(2):437-42.
102. Cea-Soriano L, Johansson S, Garcia Rodriguez LA. Risk factors for falls with use of acid-suppressive drugs. Epidemiology. 2013;24(4):600-7.
103. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947-53.
104. Corley DA, Kubo A, Zhao W, Quesenberry C. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology. 2010;139(1):93-101.
105. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179(4):319-26.
106. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 2006;79(2):76-83.
107. Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2011;106(7):1209-18 (quiz 19).
108. Laine L. Proton pump inhibitors and bone fractures? Am J Gastroenterol. 2009;104(Suppl 2):S21-6.
109. Kwok CS, Yeong JK, Loke YK. Meta-analysis: risk of fractures with acid-suppressing medication. Bone. 2011;48(4):768-76.
110. Food and Drug Administration. FDA Drug Safety Communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm213206.htm. Accessed 8 Aug 2013.
111. Moayyedi P, Yuan Y, Leontiadis G, Affairs obotCC. Canadian Association of Gastroenterology position statement: hip fracture and proton pump inhibitor therapy - a 2013 update. Can J Gastroenterol. 2013;27(10):593-5.
112. Inglis TJ, Sherratt MJ, Sproat LJ, Gibson JS, Hawkey PM. Gastroduodenal dysfunction and bacterial colonisation of the ventilated lung. Lancet. 1993;341(8850):911-3.
113. Simms HH, DeMaria E, McDonald L, Peterson D, Robinson A, Burchard KW. Role of gastric colonization in the development of pneumonia in critically ill trauma patients: results of a prospective randomized trial. J Trauma. 1991;31(4):531-6 (discussion 6-7).
114. Puisieux F, D'Andrea C, Baconnier P, Bui-Dinh D, Castaings-Pelet S, Crestani B, et al. Swallowing disorders, pneumonia and respiratory tract infectious disease in the elderly. Rev Mal Respir. 2011;28(8):e76-93.
115. Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ. 2011;183(3):310-9.
116. el-Serag HB, Sonnenberg A. Comorbid occurrence of laryngeal or pulmonary disease with esophagitis in United States military veterans. Gastroenterology. 1997;113(3):755-60.
117. Filion KB, Chateu D, Targownik LE, Gershon A, Duran M, Tamim H, et al. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut. 2014;63(4):552-8.
118. Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med. 2007;167(9):950-5.
119. Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med. 2008;149(6):391-8.
120. Torres A, El-Ebiary M, Soler N, Monton C, Fabregas N, Hernandez C. Stomach as a source of colonization of the respiratory tract during mechanical ventilation: association with ventilator-associated pneumonia. Eur Respir J. 1996;9(8):1729-35.
121. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA. 1996;275(2):134-41.
122. Stabler SP. Clinical practice. Vitamin B12 deficiency. N Engl J Med. 2013;368(2):149-60.
123. Murphy MF, Sourial NA, Burman JF, Doyle DV, Tabaqchali S, Mollin DL. Megaloblastic anaemia due to vitamin B12 deficiency caused by small intestinal bacterial overgrowth: possible role of vitamin B12 analogues. Br J Haematol. 1986;62(1):7-12.
124. Steinberg WM, King CE. Toskes PP. Malabsorption of protein-bound cobalamin but not unbound cobalamin during cimetidine administration. Dig Dis Sci. 1980;25(3):188-91.
125. Marcuard SP, Albernaz L, Khazanie PG. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann Intern Med. 1994;120(3):211-5.
126. Saltzman JR, Kemp JA, Golner BB, Pedrosa MC, Dallal GE, Russell RM. Effect of hypochlorhydria due to omeprazole treatment or atrophic gastritis on protein-bound vitamin B12 absorption. J Am Coll Nutr. 1994;13(6):584-91.
127. Schenk BE, Festen HP, Kuipers EJ, Klinkenberg-Knol EC, Meuwissen SG. Effect of short- and long-term treatment with omeprazole on the absorption and serum levels of cobalamin. Aliment Pharmacol Ther. 1996;10(4):541-5.
128. Termanini B, Gibril F, Sutliff VE, Yu F, Venzon DJ, Jensen RT. Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. Am J Med. 1998;104(5):422-30.
129. Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol. 2004;57(4):422-8.
130. Dharmarajan TS, Kanagala MR, Murakonda P, Lebelt AS, Norkus EP. Do acid-lowering agents affect vitamin B12 status in older adults? J Am Med Dir Assoc. 2008;9(3):162-7.
131. Lindenbaum J, Rosenberg IH, Wilson PW, Stabler SP, Allen RH. Prevalence of cobalamin deficiency in the Framingham elderly population. Am J Clin Nutr. 1994;60(1):2-11.
132. Pennypacker LC, Allen RH, Kelly JP, Matthews LM, Grigsby J, Kaye K, et al. High prevalence of cobalamin deficiency in elderly outpatients. J Am Geriatr Soc. 1992;40(12):1197-204.
133. Carmel R, Perez-Perez GI, Blaser MJ. Helicobacter pylori infection and food-cobalamin malabsorption. Dig Dis Sci. 1994;39(2):309-14.
134. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, Bloemena EC, Sandell M, Nelis GF, et al. Atrophic gastritis during long-term omeprazole therapy affects serum vitamin B12 levels. Aliment Pharmacol Ther. 1999;13(10):1343-6.
135. Sagar M, Janczewska I, Ljungdahl A, Bertilsson L, Seensalu R. Effect of CYP2C19 polymorphism on serum levels of vitamin B12 in patients on long-term omeprazole treatment. Aliment Pharmacol Ther. 1999;13(4):453-8.
136. Kapadia C. Cobalamin (Vitamin B12) deficiency: is it a problem for our aging population and is the problem compounded by drugs that inhibit gastric acid secretion? J Clin Gastroenterol. 2000;30(1):4-6.
137. Howden CW. Vitamin B12 levels during prolonged treatment with proton pump inhibitors. J Clin Gastroenterol. 2000;30(1):29-33.
138. Schade SG, Cohen RJ, Conrad ME. Effect of hydrochloric acid on iron absorption. N Engl J Med. 1968;279(13):672-4.
139. Bezwoda W, Charlton R, Bothwell T, Torrance J, Mayet F. The importance of gastric hydrochloric acid in the absorption of nonheme food iron. J Lab Clin Med. 1978;92(1):108-16.
140. Stewart CA, Termanini B, Sutliff VE, Serrano J, Yu F, Gibril F, et al. Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy. Aliment Pharmacol Ther. 1998;12(1):83-98.
141. Hutchinson C, Geissler CA, Powell JJ, Bomford A. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut. 2007;56(9):1291-5.
142. Guyatt GH, Patterson C, Ali M, Singer J, Levine M, Turpie I, et al. Diagnosis of iron-deficiency anemia in the elderly. Am J Med. 1990;88(3):205-9.
143. Andres E, Federici L, Serraj K, Kaltenbach G. Update of nutrient-deficiency anemia in elderly patients. Eur J Intern Med. 2008;19(7):488-93.
144. Gaskell H, Derry S, Andrew Moore R, McQuay HJ. Prevalence of anaemia in older persons: systematic review. BMC Geriatr. 2008;8:1.
145. Hodges K, Gill R. Infectious diarrhea: cellular and molecular mechanisms. Gut Microbes. 2010;1(1):4-21.
146. Kuipers EJ, Surawicz CM. Clostridium difficile infection. Lancet. 2008;371(9623):1486-8.
147. Gravel D, Miller M, Simor A, Taylor G, Gardam M, McGeer A, et al. Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study. Clin Infect Dis. 2009;48(5):568-76.
148. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353(23):2442-9.
149. Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11(5):483-90.
150. Food and Drug Administration. FDA Drug Safety communication: proton pump inhibitors (PPIs) - drug safety communication: Clostridium difficile-associated diarrhea (CDAD) can be associated with stomach acid drugs. http://www.fda.gov/ Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm290838. htm. Accessed 16th Aug 2013.
151. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102(9):2047-56 (quiz 57).
152. Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol. 2012;107(7):1001-10.
153. Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol. 2012;107(7):1011-9.
154. Rothman KJ. Measuring interactions. In: Epidemiology: an introduction. Oxford: University Press; 2002.
155. Giannella RA, Broitman SA, Zamcheck N. Gastric acid barrier to ingested microorganisms in man: studies in vivo and in vitro. Gut. 1972;13(4):251-6.
156. Doorduyn Y, Van Den Brandhof WE, Van Duynhoven YT, Wannet WJ, Van Pelt W. Risk factors for Salmonella enteritidis and typhimurium (DT104 and non-DT104) infections in The Netherlands: predominant roles for raw eggs in Enteritidis and sandboxes in typhimurium infections. Epidemiol Infect. 2006;134(3):617-26.
157. Doorduyn Y, Van Pelt W, Siezen CL, Van Der Horst F, Van Duynhoven YT, Hoebee B, et al. Novel insight in the association between salmonellosis or campylobacteriosis and chronic illness, and the role of host genetics in susceptibility to these diseases. Epidemiol Infect. 2008;136(9):1225-34.
158. Garcia Rodriguez LA, Ruigomez A, Panes J. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol. 2007;5(12):1418-23.
159. Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med. 2006;355(17):1834-6.
160. Kuipers MT, Thang HD, Arntzenius AB. Hypomagnesaemia due to use of proton pump inhibitors-a review. Neth J Med. 2009;67(5):169-72.
161. Faulhaber GA, Ascoli BM, Lubini A, Mossmann M, Rossi G, Geib G, et al. Serum magnesium and proton-pump inhibitors use: a cross-sectional study. Rev Assoc Med Bras. 2013;59(3):276-9.
162. Broeren MA, Geerdink EA, Vader HL, van den Wall Bake AW. Hypomagnesemia induced by several proton-pump inhibitors. Ann Intern Med. 2009;151(10):755-6.
163. Hoorn EJ, van der Hoek J, de Man RA, Kuipers EJ, Bolwerk C, Zietse R. A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis. 2010;56(1):112-6.
164. Shabajee N, Lamb EJ, Sturgess I, Sumathipala RW. Omeprazole and refractory hypomagnesaemia. BMJ. 2008;337:a425.
165. Food and Drug Administration. Proton pump inhibitor drugs (PPIs): drug safety communication - low magnesium levels can be associated with long-term use. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ safetyAlertsforHumanMedicalProducts/ucm245275.htm. Accessed 20th Aug 2013.
166. Serfaty-Lacrosniere C, Wood RJ, Voytko D, Saltzman JR, Pedrosa M, Sepe TE, et al. Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J Am Coll Nutr. 1995;14(4):364-8.
167. Shah GM, Kirschenbaum MA. Renal magnesium wasting associated with therapeutic agents. Miner Electrolyte Metab. 1991;17(1):58-64.
168. Perazella MA, Markowitz GS. Drug-induced acute interstitial nephritis. Nat Rev Nephrol. 2010;6(8):461-70.
169. Sierra F, Suarez M, Rey M, Vela MF. Systematic review: proton pump inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther. 2007;26(4):545-53.
170. Simpson IJ, Marshall MR, Pilmore H, Manley P, Williams L, Thein H, et al. Proton pump inhibitors and acute interstitial nephritis: report and analysis of 15 cases. Nephrology (Carlton). 2006;11(5):381-5.
171. Helsby NA, Lo WY, Simpson IJ, Voss DM, Logan KE, Searle M, et al. Omeprazole-induced acute interstitial nephritis is not related to CYP2C19 genotype or CYP2C19 phenotype. Br J Clin Pharmacol. 2010;69(5):516-9.